Regulators' rejection of a tamper-resistant pain drug from Pain Therapeutics Inc.and Pfizer Inc. could delay approval of the drug for a year or more.
San Mateo-based Pain Therapeutics (NASDAQ: PTIE) said the Food and Drug Administration cited the inconsistent release of some lots of Remoxy, designed to be a sustained-release version of oxycodone.
No comments:
Post a Comment